VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

The phase III MAX clinical trial randomised patients with metastatic colorectal cancer (mCRC) to receive first-line capecitabine chemotherapy alone or in combination with the anti-VEGF-A antibody bevacizumab (± mitomycin C). We utilised this cohort to examine whether single nucleotide polymorphisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Chionh, Fiona, Gebski, Val, Al-Obaidi, Sheren J., Mooi, Jennifer K., Bruhn, Maressa A., Lee, Chee K., Chüeh, Anderly C., Williams, David S., Weickhardt, Andrew J., Wilson, Kate, Scott, Andrew M., Simes, John, Hardingham, Jennifer E., Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786898/
https://www.ncbi.nlm.nih.gov/pubmed/35075138
http://dx.doi.org/10.1038/s41598-021-03952-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786898/
https://www.ncbi.nlm.nih.gov/pubmed/35075138
http://dx.doi.org/10.1038/s41598-021-03952-y

Ejemplares similares